Cyclobutyl benzimidazoles as PDE 10 inhibitors

Patent metadata

Field	Value
Publication number	US-9284302-B2
Application number	US-201314442963-A
Country	US
Kind code	B2
Filing date	Nov 11, 2013
Priority date	Nov 15, 2012
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

The present invention is directed to substituted cyclobutyl benzimidazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

First claim

What is claimed is:

1. A compound of the formula I:

wherein:
each R, and R x independently represent H, OH, halogen, or C 1-6 alkyl,
R c represents H, OH, halogen, —C(R) 2 OR, or C 1-6 alkyl,
R 2 is selected from the group consisting of H, O—R, CN, O(CH 2 ) n OR, OCHR(CH2) n OR, SR, SO 2 R, S(O)R, N(R) 2 , C(O)N(R) 2 , C 1-3 haloalkyl, O(CH 2…

Assignees

• Merck Sharp & Dohme

Inventors

• Kuduk Scott D
• Mccomas Casey C
• Reger Thomas S

Classifications

• A61K31/4196

  Human Necessities · mapped topic

• C07D403/14 Primary

  Chemistry & Metallurgy · mapped topic

• A61K31/506

  Human Necessities · mapped topic

• A61K31/4184

  Human Necessities · mapped topic

• A61P25/14

  Human Necessities · mapped topic